Skip to main content
OpenTrials
Completed

NCT Number: NCT05811286

The Use of a Morcellator in Operative Hysteroscopy for Benign Intracavitary Lesions: a Feasibility Study

Polyps, intracavitary myomas and retained products of conception (RPOC) are common benign intracavitary lesions of the uterus and frequently cause abnormal uterine bleeding or pain. In general, intracavitary lesions are treated by operative hysteroscopy with bipolar resectoscopic removal under general anaesthesia, performed in the theatre (OR). Potential problems with this approach are thermal damage and impairment of visibility due to loose tissue fragments necessitating multiple entries for tissue removal.

Recently, lesion morcellation by hysteroscopy has been introduced as an alternative technique. Compared to the resectoscopic approach, morcellation is reportedly associated with a shorter total procedure time, smaller fluid deficit and number of insertions. A few trials also registered a higher success rate in completeness of resection.

No significant differences in odds of surgical complications have been reported.

Most hysteroscopic morcellators have diameters up to 8 mm, for which cervical dilation under general anaesthesia is usually needed.

Recently, companies have developed hysteroscopic morcellators with smaller diameters, e.g. 6.3 mm for the 19 Fr. intrauterine BIGATTI Shaver (IBS®). This means less need for cervical dilation, and potential use without anesthesia.

At this moment, there are no prospective studies available on feasibility of the 19 Fr. intrauterine BIGATTI Shaver (IBS®). Before implementing hysteroscopic morcellation in our department, we need a feasibility study assessing the method in standard conditions in the operation room or in ambulatory setting under sedation.

Trial objectives:

Assessment of the feasibility of hysteroscopic morcellation of benign uterine intracavitary lesions. The primary objective is to assess the completeness of hysteroscopic resection in patients undergoing the procedure under general anesthesia or sedation.

Secondary objectives are to assess perioperative parameters as operation time, need for cervical dilation, adverse events, pain, operator satisfaction; to assess quality of tissue for histological examination; to assess postoperative complications and pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ziekenhuis Oost-Limburg, Genk, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients:
  • Female

Ultrasonographic diagnosis of an intracavitary lesion, according the IETA terms and definitions

  • endometrial polyp
  • FIGO 0-1 myoma (maximum diameter 2 cm)
  • RPOC (maximum diameter 2 cm, no enhanced myometrial vascularity)

Exclusion criteria

  • • Active vaginal bleeding
  • (possible) malignancy
  • < 18y
  • Patient refusal
  • Pregnancy
  • Impossibility to access the uterine cavity (e.g. severe cervical stenosis)
  • Absence of intracavitary lesion (endometrial polyp, FIGO 0-1 myoma or RPOC) at hysteroscopy

Treatment and study plan

Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions

Procedure

With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception.

We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain.

Primary outcomes

  1. Completeness of resection of intracavitary lesions in 50 patients, when using a hysteroscopic Bigatti Shaver.

    Time frame: During surgery

    If all tissue could be removed by the 19 Fr. intrauterine BIGATTI Shaver by direct visualisation at the end of the hysteroscopic procedure and at post-operative ultrasound evaluation.

Secondary outcomes

  1. Operation time

    Time frame: During surgery

    total operation time and time necessary for the morcellation

  2. Need for cervical dilation during procedure

    Time frame: During surgery

    Was it necessary to perform any dilatation with

  3. Volume of distension fluid used / loss (deficit) during procedure

    Time frame: During surgery

    Deficit in fluid used during surgery?

  4. Operator satisfaction, assessed by verbal rating scale

    Time frame: At the end of the procedure

    Operator satisfaction in terms of technique, ergonomics and general proceedings.

    The verbal rating scale includes Very negative; Negative; Intermediate; Positive; Very positive.

  5. Complications

    Time frame: 6 weeks after surgery

    Adverse events during procedure/hospitalization and within the first 6 weeks after procedure

  6. Pain on the first postoperative day, assessed by verbal rating scale

    Time frame: Day 1 post-operatively

    Pain on the first day post-operatively. The verbal rating scale includes Very negative; Negative; Intermediate; Positive; Very positive.

  7. Histology of the intracavitary lesion

    Time frame: 6 weeks post-operatively

    Incidence of histological outcomes such as endometrial polyps, intracavitary myomas or remnant products of conception.

    This is a categorical variable.

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Collaborators

  • Ziekenhuis Oost-Limburg

Registry information

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Apr 13, 2023
Registry last updated
Jul 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.